NCT00461812 is a Phase 4 clinical trial of Mometasone in Asthma, sponsored by Johns Hopkins University.

Who is sponsoring NCT00461812?

NCT00461812 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT00461812?

Interventions in NCT00461812: Mometasone, Advair.

Is NCT00461812 still recruiting?

NCT00461812 is currently terminated. Last updated 19 September 2017.

Are results published for NCT00461812?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-09-19 · How we verify

NCT00461812

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-Blind, Randomized, Positive-controlled Study to Compare Monotherapy With an Inhaled Corticosteroid (Mometasone) to Combination Therapy With an Inhaled Corticosteroid + a Long-Acting Bronchodilator (Advair) in Patients With Milder Persistent Asthma

Terminated Phase 4 Results posted Last updated 19 September 2017

What this trial tests

Phase 4 trial testing Mometasone in Asthma in 33 participants. Terminated before completion.

Timeline

1 April 2007

Primary endpoint
19 January 2010

19 January 2010

Quick facts

Lead sponsor	Johns Hopkins University
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	33
Start date	1 April 2007
Primary completion	19 January 2010
Estimated completion	19 January 2010
Sites	1 location across United States

Drugs / interventions tested

Mometasone — full drug profile →
Advair — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Johns Hopkins University

Who can join

Adults 18 to 65, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Efficacy as Assessed my Pulmonary Function Tests
Time frame: change from baseline to study completion

Sponsor's own description

The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma? The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50, when measured by this standard methodology (methacholine bronchoprovocation) in subjects with mild persistent asthma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.
Crossingham I, Turner S, Ramakrishnan S, Fries A, et al · · 2021 · cited 41× · PMID 33945639 · DOI 10.1002/14651858.cd013518.pub2

Verify or expand the search:

Other trials of Mometasone

Trials testing the same drug.

NCT05311475 — Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-gro · Phase 3 · completed
NCT03758950 — Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2 · Phase 2 · completed
NCT00783237 — Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431) · Phase 4 · completed
NCT00070707 — Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280) · Phase 4 · completed
NCT00763529 — Elocon vs Fluticasone in Localized Psoriasis (P03197) · Phase 4 · completed

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00461812 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 19 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00461812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing